Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC)
Titel:
Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC)
Auteur:
Noviello, D. Fries, W. Orlando, A. Conforti, F.S. Bezzio, C. Castiglione, F. Fantini, M.C. Savarino, E.V. Festa, S. Ribaldone, D.G. Mocci, G. Grossi, L. ViganĂ², C. Imperatore, N. Ceccarelli, L. Gabrielli, A.M. Carvalhas Scardino, G. Saibeni, S. Balestrieri, P. Principi, M. Campigotto, M. Gravina, A.G. Spagnuolo, R. Scaldaferri, F. Neri, B. Sario, A. Di Baldoni, M. Mitri, R. Di Tettoni, E. Calderone, S. Armuzzi, A. Macaluso, F.S. Vecchi, M. Ventimiglia, M. Caprioli, F.